Puan Rozlina Lajis

Head of New Drug Product Section, NPRA

Rosliza Lajis completed her Master of International Health Economics and Pharmacoeconomics from the Cardiff University, United Kingdom and her pharmacy undergraduate studies at Bandung Institute of Technology, Indonesia, in 2011 and 2001, respectively. The latter was funded by Public Service Department Scholarship.
In 2002, she joined the Ministry of Health (MoH) Malaysia and since March 2020 she has lead the New Drug Product Section, Centre of Product & Cosmetic Evaluation, National Pharmaceutical Regulatory Agency (NPRA) to date.

Rosliza’s expertise covers all matters of Access to Medicine and she is highly involved in international and local discussions pertaining to Drug Accessibility, Formulary Management, Pharmacoeconomics & Health Economics and Managed Entry Agreements (MEAs) from 2011 till 2019. Her current interest is focused on the areas of good reliance practice and collaborative assessment initiatives as part of a strategy towards facilitating an earlier access to a quality-assured, safe and effective medicines.

All Sessions by Puan Rozlina Lajis

1:30 pm - 2:00 pm

Registration Requirements for Cannabis Based Medicine